

DAFTAR PUSTAKA

1. Ginjal Kronis [Internet]. Direktorat P2PTM. 2017. [Diakses 16 November 2023, 00:10 WIB] Tersedia di: <https://p2ptm.kemkes.go.id/kegiatan-p2ptm/subdit-penyakit-jantung-dan-pembuluh-darah/ginjal-kronis>
2. Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, et al. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. Remuzzi G, editor. PLOS ONE. 2016 Jul 6;11(7)
3. PERNEFRI. 11th Report of Indonesian renal registry 2018. Jakarta: Perhimpunan Nefrologi Indonesia. 2018
4. KDIGO CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. 2013.
5. Yu ASL, Chertow GM, Luyckx VA, Marsden PA, Skorecki K, Taal MW. Brenner & Rector's the kidney. [Philadelphia, PA]: Elsevier; 2020.
6. Teerlink T, Luo Z, Palm F, Wilcox CS. Cellular ADMA: Regulation and action. Pharmacological Research. 2009 Dec;60(6):448–60.
7. Dowsett L, Higgins E, Alanazi S, Alshuwayer NA, Leiper FC, Leiper J. ADMA: A Key Player in the Relationship between Vascular Dysfunction and Inflammation in Atherosclerosis. Journal of Clinical Medicine. 2020; 9(9):3026.
8. Kielstein J, Boger R, Bode-boger SM. Asymmetric dimethylarginine plasma concentrations differ in patients with end stage renal disease: relationship to treatment method and atherosclerotic disease. Journal of the American Society of Nephrology. 1999 Mar;10(3):594–600.
9. Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. American Journal of Physiology Heart and Circulatory Physiology. 2007 Dec;293(6):H3227-3245.
10. Wilcox CS. Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2005 Oct;289(4):R913–35.
11. Vallance P, Leiper J. Asymmetric Dimethylarginine and Kidney Disease—Marker or Mediator? Journal of The American Society of Nephrology. 2005 Aug 1;16(8):2254–6.
12. Asmarawati TP, Widodo W, Thaha M, Aditiawardana A, Mardiana N, Ardhanay AR, et al. Comparison of Asymmetric Dimethylarginine Levels Between Stages Three, Four, and Five Non-dialysis of Chronic Kidney Disease. PubMed. 2016 Jan 1;48(1):28–34.
13. Lu TM, Chung MY, Lin CC, Hsu CP, Lin SJ. Asymmetric Dimethylarginine and Clinical Outcomes in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology. 2011 Jun 3;6(7):1566–72.
14. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical Dimethylarginine Predicts Progression to Dialysis and Death in Patients with Chronic Kidney Disease: A Competing Risks Modeling Approach. Journal of the American Society of Nephrology. 2005 Jun 8;16(8):2449–55.

15. USRDS. 2018 USRDS Annual Data Report: Executive Summary. *American Journal of Kidney Diseases*. 2019 Mar;73(3):A9–22.
16. Setiati S, Alwi I, Sudoyo A W, Stiyohadi B, Syam A F. *Buku Ajar Ilmu Penyakit Dalam Jilid II. Edisi-VI*. Jakarta: Interna Publishing; 2017.
17. Cunha RS da, Santos AF, Barreto FC, Stinghen AEM. How do Uremic Toxins Affect the Endothelium? *Toxins*. 2020 Jun 20;12(6):412.
18. Effendi I, Pasaribu R. Edema patofisiologi dan penanganannya. Dalam: Setiati S, Alwi I, Sudoyo A W, Stiyohadi B, Syam A F. *Buku Ajar Ilmu Penyakit Dalam Jilid II. Edisi-VI*. Jakarta: Interna Publishing; 2017
19. Bello AK, Alrukhaimi M, Ashuntantang GE, Basnet S, Rotter RC, Douthat WG, et al. Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action. *Kidney International Supplements*. 2017 Oct;7(2):122–9.
20. Damtie S, Biadgo B, Baynes HW, Ambachew S, Melak T, Asmelash D, Abebe M. Chronic Kidney Disease and Associated Risk Factors Assessment among Diabetes Mellitus Patients at A Tertiary Hospital, Northwest Ethiopia. *Ethiopian Journal of Health Sciences*. 2018 Nov;28(6):691-700.
21. Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, Jafar T, Jassal SK, Landman GW, Muntner P, Roderick P, Sairenchi T, Schöttker B, Shankar A, Shlipak M, Tonelli M, Townsend J, van Zuilen A, Yamagishi K, Yamashita K, Gansevoort R, Sarnak M, Warnock DG, Woodward M, Ärnlöv J; CKD Prognosis Consortium. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. *Lancet Diabetes Endocrinol*. 2015 Jul;3(7):514-25.
22. Levey A, Inker L. Assessment of Glomerular Filtration Rate in Health and Disease: A State of the Art Review. *Clinical Pharmacology & Therapeutics*. 2017 Jun;102(3):405–19. [Diakses 16 November 2023, 00:15 WIB]. Tersedia di: <https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.729>
23. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoute PM. Endothelial dysfunction in diabetes. *British Journal of Pharmacology*. 2000 Jul;130(5):963–74.
24. Furchgott RF. The Discovery of Endothelium-Derived Relaxing Factor and Its Importance in the Identification of Nitric Oxide. *JAMA: The Journal of the American Medical Association*. 1996 Oct 9;276(14):1186.
25. Schulz E, Jansen T, Wenzel P, Daiber A, Münzel T. Nitric Oxide, Tetrahydrobiopterin, Oxidative Stress, and Endothelial Dysfunction in Hypertension. *Antioxidants & Redox Signaling*. 2008 Jun;10(6):1115–26.
26. Sydow K. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocysteinemia: effects of L-arginine and B vitamins. *Cardiovascular Research*. 2003 Jan;57(1):244–52.
27. Hadi AR, Carr CS, Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy and outcome. *Vasc Health and Risk Management*. 2005 ;1(3):183-98.
28. Damaso E O, Nestor O D, Fransisco R, Juan P, Eduardo B, Fayna G, et al. Asymmetric (ADMA) and Symetric (SDMA) Dimethylarginine in Chronic

- Kidney Disease: A Clinical Approach. *International Journal of Molecular Sciences*. 2019 ;20(15):3668.
29. Kasumov T, Edmison JM, Dasarathy S, Bennett C, Lopez R, Kalhan SC. Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease. *Metabolism*. 2011 Jun;60(6):776–81.
 30. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Böger SM, Haller H, et al. Asymmetric Dimethylarginine and Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease Study. *Journal of the American Society of Nephrology*. 2005 Jun 1;16(8):2456–61.
 31. Fujimi-Hayashida A, Ueda S, Yamagishi S, Kaida Y, Ando R, Nakayama Y, et al. Association of Asymmetric Dimethylarginine with Severity of Kidney Injury and Decline in Kidney Function in IgA Nephropathy. *American Journal of Nephrology*. 2010 Nov 26;33(1):1–6.
 32. Morris ST, McMurray JJ, Rodger RS, Jardine AG. Impaired endothelium-dependent vasodilatation in uraemia. *Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association*. 2000 Aug 1;15(8):1194–200.
 33. Thambyrajah J, Landray MJ, McGlynn FJ, et al. Abnormalities of endothelial function in patients with predialysis renal failure. *Heart*. 2000 Feb 1;83(2):205–9.
 34. Zoccali C. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. *Journal of Hypertension*. 2006 Apr;24(4):611–9.
 35. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. *The Lancet*. 2001 Dec;358(9299):2096–7.
 36. Böger RH, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk. *Pharmacological Research*. 2009 Dec 1;60(6):481–7.
 37. Cooke JP. Does ADMA Cause Endothelial Dysfunction? *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2000 Sep;20(9):2032–7.
 38. Madaric J, Valachovicova M, Paulis L, Pribojova J, Mateova R, Sebekova K, Postulkova L, Madaricova T, Bucova M, Mistrik M, Vulev I. Improvement in asymmetric dimethylarginine and oxidative stress in patients with limb salvage after autologous mononuclear stem cell application for critical limb ischemia. *Stem Cell Research & Therapy*. 2017 Jul 12;8(1)
 39. Hakim LN. Urgensi Revisi Undang-Undang tentang Kesejahteraan Lanjut Usia. *Aspirasi: Jurnal Masalah-masalah Sosial*. 2020 Jun 30;11(1):43–55.
 40. Mills KT, Xu Y, Zhang W, Bundy JD, Chen CS, Kelly TN, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. *Kidney International*. 2015 Nov;88(5):950–7.
 41. National Kidney Foundation. Kidney Failure Risk Factor: Gender (Sex) [Internet]. National Kidney Foundation. 2020. [Diakses 8 Januari 2024, 19:43 WIB]. Tersedia di: <https://www.kidney.org/content/kidney-failure-risk-factor-gender-sex>
 42. Glassock RJ, Winearls CG. Ageing and the glomerular filtration rate: truths and consequences. *PubMed*. 2009 Jan 1;

43. Chadban SJ. Prevalence of Kidney Damage in Australian Adults: The AusDiab Kidney Study. *Journal of the American Society of Nephrology*. 2003 Jul 1;14(90002):131S138.
44. MacRae C, Mercer SW, Guthrie B, Henderson D. Comorbidity in chronic kidney disease: a large cross-sectional study of prevalence in Scottish primary care. *British Journal of General Practice*. 2020 Dec 9;71(704):e243–9.
45. Lee WC, Lee YT, Li LC, Ng HY, Kuo WH, Lin PT, et al. The Number of Comorbidities Predicts Renal Outcomes in Patients with Stage 3–5 Chronic Kidney Disease. *Journal of Clinical Medicine*. 2018 Nov 28;7(12).
46. Fraser SDS, Roderick PJ, May CR, McIntyre N, McIntyre C, Fluck RJ, et al. The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study. *BMC Nephrology*. 2015 Dec;16(1).
47. Eiselt J, Rajdl D, Racek J, Vostrý M, Rulcová K, Wirth J. Asymmetric Dimethylarginine and Progression of Chronic Kidney Disease - a One-Year Follow-Up Study. *Kidney and Blood Pressure Research*. 2014;39(1):50–7.
48. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Böger SM, Haller H, et al. Asymmetric Dimethylarginine and Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease Study. *Journal of the American Society of Nephrology*. 2005 Jun 1;16(8):2456–61.
49. Guo X, Xing Y, Jin W. Role of ADMA in the pathogenesis of microvascular complications in type 2 diabetes mellitus. *Frontiers in Endocrinology*. 2023 Apr 21;14.
50. Triches CB, Quinto M, Mayer S, Batista M, Zanella MT. Relation of asymmetrical dimethylarginine levels with renal outcomes in hypertensive patients with and without type 2 diabetes mellitus. *Journal of Diabetes and its Complications*. 2018 Mar 1;32(3):316–20.
51. Lajer M, Tarnow L, Jorsal A, Teerlink T, Parving HH., Rossing P. Plasma Concentration of Asymmetric Dimethylarginine (ADMA) Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients With Diabetic Nephropathy. *Diabetes Care*. 2007 Dec 27;31(4):747–52.
52. Ueda S, Yamagishi SI, Kaida Y, Okuda S. Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease (Review Article). *Nephrology*. 2007 Dec;12(6):582–90.
53. Kielstein JT, B. Imprim, Simmel S, Bode-Böger SM, Dimitrios Tsikas, Frölich JC, et al. Cardiovascular Effects of Systemic Nitric Oxide Synthase Inhibition With Asymmetrical Dimethylarginine in Humans. 2004 Jan 20;109(2):172–7.